<DOC>
	<DOC>NCT00521365</DOC>
	<brief_summary>The primary purpose of the study is to assess the efficacy of Quetiapine extended release 600mg per day either as monotherapy or combined therapy in the treatment of patients with mania associated to Bipolar disorder. This trial will also assess the life quality and productivity loss improvement for patients from baseline to day 21.</brief_summary>
	<brief_title>Effectiveness of Quetiapine XR on the Control of Symptoms of Manic Phase of Bipolar Disorder.</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Affective Disorders, Psychotic</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Patients with type I Bipolar Disorder in Manic phase according to standard scales and physician criteria. Patients of both genders, aged 1865 years old being at the first episode Patients with chronic Bipolar Disorder with at least one previous manic episode 6 months before inclusion, that based on the physician experience are in a manic episode at study entry quality Psychoactive substance or alcohol abuse or dependence, forbidden medication, pregnancy, rapid cycling patients, intolerance to Quetiapine, clinically severe disease, unstable Diabetes Mellitus, neutropenia, other laboratory abnormalities</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Bipolar Disorder</keyword>
	<keyword>Bipolar Affective Psychosis</keyword>
	<keyword>Mania</keyword>
	<keyword>Manic Disorder</keyword>
	<keyword>Manic State</keyword>
</DOC>